Amgen Spinoff Atara Biotherapeutics Hikes IPO Target From $50 Million To $92 Million
Atara Biotherapeutics Inc. supersized its planned IPO to up to $92 million, offering 5.75 million shares at a range of $14 to $16 each.
The Brisbane spinout of Amgen Inc., which counts among its investors legendary Mexican billionaire Carlos Slim, last month eyed a $50 million initial public offering. Now it is the second Bay Area life sciences company this week to raise its IPO target.
Help employers find you! Check out all the jobs and post your resume.